Korea Readying Itself For New Era Of Digital Therapeutics
Pivotal Trials Underway But Reimbursement Lacking
Executive Summary
Scrip takes a look at the current landscape in the South Korean digital therapeutics sector, where some remaining gaps in regulation and reimbursement are seen but multiple products are now progressing through pivotal local clinical trials.
You may also be interested in...
Korea’s Key Words For 2023: Regulatory Innovation, Digital Healthcare
The Pink Sheet’s roundup of key regulatory issues in Korea for 2022 and outlook for this year.
From Science To Commercialization: How Genexine Is Making The Shift
Genexine CEO Neil Warma talks to Scrip in this audio interview about a wide range of topics, including key strategy changes, ambitions to become a leading global biopharma, as well as challenges he has faced since joining the Korean biotech.
Korean Industry Demands Bold Support Amid US Policy Moves
As the global biopharma industry attempts to understand the implications of the US Inflation Reduction Act, South Korea's biopharma industry is pressing its government to come up with "bold and rapid" additional measures to reduce the possible negative impact of the legislation and other US policies with international implications, and to support the sector amid generally rising global competition.